Founded in 1990, The United Laboratories International Holdings Limited (TUL) is a pharmaceutical group integrating R&D, production and sales, with more than 15,000 employees. In 2007, TUL (stock code: 3933) was listed on the Hong Kong Stock Exchange.

 Since its establishment, TUL has been committed to the philosophy “make life more valuable”, extending its product mix from antibiotics to biopharmaceuticals and animal pharmaceuticals, and continuously optimizing its vertically integrated business model. At present, TUL has six production bases, and its products cover medical intermediates, active pharmaceutical ingredients (APIs) and pharmaceutical preparations, with a global sales network.

 Boasting strong strength in R&D and production and robust marketing ability, TUL was awarded a great number of honors such as the 20th among the “China Top 100 Pharmaceutical Industry Companies in 2020”, “China Top 100 Industrial Enterprises with Comprehensive Strength in the Chemical Pharmaceutical Industry in 2020”, and the 16th among “China Top 100 Chemical Pharmaceutical Enterprises in 2022”, “Excellent Enterprise Brand for Pharmaceutical Preparation Export” and “Excellent Enterprise Brand for APIs Export” in China’s Chemical Pharmaceutical Industry in 2021.